person · Reporting owner
Washburn Theodore James Jr.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Principal Accounting Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 868 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Sale · Disposed 5,272 · Balance 868 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 5,272 | $28.88 | $152,255.36 |
DisclosureSEC source: 0001439222-26-000046 · wk-form4_1772744891.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868 Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · derivative · entry 10 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,390 Underlying: Common stock · 2,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · derivative · entry 9 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,450 Underlying: Common stock · 2,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · derivative · entry 8 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 798 | $28.96 | $23,110.08 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 6 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,140 F4 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 5 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 727 | $28.96 | $21,053.92 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,243 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 698 | $28.96 | $20,214.08 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,595 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 75 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 8,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000034 · wk-form4_1772572356.xml · derivative · entry 7 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,452 Underlying: Common stock · 8,452 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. F6 · derivative.expiration_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 8,546 | $36.87 | $315,091.02 |
DisclosureSEC source: 0001439222-25-000102 · wk-form4_1757449574.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · derivative · entry 11 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,900 Underlying: Common stock · 2,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F10 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F10 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 727 | $35.54 | $25,837.58 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 6 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,414 F4 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 697 | $35.54 | $24,771.38 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,691 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 231 | $35.54 | $8,209.74 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,038 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · derivative · entry 10 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,350 Underlying: Common stock · 2,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · derivative · entry 9 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · derivative · entry 8 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,142 Underlying: Common stock · 6,142 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. On February 1, 2027, the shares underlying the restricted stock units will vest in full. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. On February 1, 2027, the shares underlying the restricted stock units will vest in full. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 8,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · derivative · entry 7 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,085 Underlying: Common stock · 8,085 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F6 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 5 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000011 · wk-form4_1741122407.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 05, 2025 Filed Feb 5, 2025 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,272 | $34.39 | $78,134.08 |
DisclosureSEC source: 0001439222-25-000004 · wk-form4_1738789362.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,437 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 1, 2023. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 6,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000004 · wk-form4_1738789362.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 1, 2023. The shares underlying the restricted stock units will vest in full on February 1, 2025 F3 · derivative.expiration_date: The restricted stock units were granted on February 1, 2023. The shares underlying the restricted stock units will vest in full on February 1, 2025 Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000004 · wk-form4_1738789362.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 772 | $56.09 | $43,301.48 |
DisclosureSEC source: 0001439222-24-000144 · wk-form4_1731532469.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 813 F1 · balance_after: Consists of 813 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,362 | $44.39 | $60,459.18 |
DisclosureSEC source: 0001439222-24-000071 · wk-form4_1717618483.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,524 Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 919 | $32.57 | $29,931.83 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · nonDerivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,799 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 295 | $32.57 | $9,608.15 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,368 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:47 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,913 | $31.75 | $60,737.75 |
DisclosureSEC source: 0001439222-24-000056 · wk-form4_1709855269.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,886 Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · derivative · entry 7 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,700 Underlying: Common stock · 2,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · derivative · entry 6 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 777 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F6 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 7,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · derivative · entry 5 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,350 Underlying: Common stock · 7,350 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · nonDerivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000050 · wk-form4_1709673296.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 752 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:43 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 504 | $26.63 | $13,421.52 |
DisclosureSEC source: 0001439222-24-000037 · wk-form4_1708641780.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,741 Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 22:50 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 273 | $25.14 | $6,863.22 |
DisclosureSEC source: 0001439222-24-000026 · wk-form4_1707951005.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,245 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:50 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000026 · wk-form4_1707951005.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:50 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000026 · wk-form4_1707951005.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,918 | $25.39 | $74,095.90 |
DisclosureSEC source: 0001439222-23-000121 · wk-form4_1691611481.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,741 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $25.22 to $25.40. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000113 · wk-form4_1691006558.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on August 1, 2021. The shares underlying the stock units will vest in full on August 1, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested F3 · derivative.expiration_date: The restricted stock units were granted on August 1, 2021. The shares underlying the stock units will vest in full on August 1, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,232 | $26.26 | $32,352.32 |
DisclosureSEC source: 0001439222-23-000113 · wk-form4_1691006558.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,659 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000113 · wk-form4_1691006558.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 504 | $24.29 | $12,242.16 |
DisclosureSEC source: 0001439222-23-000053 · wf-form4_167822295304274.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,741 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000051 · wf-form4_167787764712794.xml · derivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 7,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000051 · wf-form4_167787764712794.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,050 Underlying: Common stock · 7,050 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 273 | $25.31 | $6,909.63 |
DisclosureSEC source: 0001439222-23-000051 · wf-form4_167787764712794.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245 Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000051 · wf-form4_167787764712794.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 73 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 233 | $27.21 | $6,339.93 |
DisclosureSEC source: 0001439222-23-000028 · wf-form4_167701349283143.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.